Sana Biotechnology (SANA) Other Non-Current Liabilities (2020 - 2026)

Sana Biotechnology has disclosed Other Non-Current Liabilities across 7 years of filings, most recently posting $9.8 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $9.8 million, up 3.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.8 million (up 3.83% YoY), and the FY2025 annual result was $83.5 million, up 743.96% from the prior year.
• Other Non-Current Liabilities came in at $9.8 million for Q1 2026 at Sana Biotechnology, down from $83.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $110.5 million in Q2 2023 to a low of $7.3 million in Q2 2024.
• The 5-year median for Other Non-Current Liabilities is $81.7 million (2022), against an average of $66.2 million.
• Across the five-year window, Other Non-Current Liabilities sank 93.39% in 2024 and surged 802.49% in 2025, its largest moves.
• Sana Biotechnology's Other Non-Current Liabilities stood at $95.0 million in 2022, then increased by 15.33% to $109.6 million in 2023, then plunged by 90.97% to $9.9 million in 2024, then soared by 743.96% to $83.5 million in 2025, then plunged by 88.26% to $9.8 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $9.8 million (Q1 2026), $83.5 million (Q4 2025), and $63.9 million (Q3 2025), per Business Quant data.